Lactic Acid Bacteria for Reducing Blue Light-Induced Eye Fatigue

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20-65
SponsorSynbio Tech Inc.

About this trial

With the widespread use of digital devices and prolonged screen exposure, digital eye strain (DES), also known as computer vision syndrome, has become a global public health concern. Emerging evidence suggests that the gut-eye axis may play an important role in ocular health, as gut microbiota imbalance is associated with systemic inflammation and oxidative stress. Specific probiotics may help alleviate eye discomfort through modulation of immune responses and enhancement of antioxidant defense mechanisms. This randomized, double-blind, placebo-controlled study aims to evaluate the efficacy of supplementation with specific probiotics, Bifidobacterium longum BL531 and Lactobacillus reuteri LR1349, in improving digital eye strain symptoms in adults.

Eligibility criteria

Qualifiers

Men and women aged 20-65 years

Daily digital screen use >6 hours for at least 1 year

Mild to severe digital eye strain (CVS-Q score ≥ 6)

Mild to moderate dry eye symptoms (OSDI ≥ 13)

Disqualifiers

Amblyopia or strabismus

Severe eye diseases (e.g., glaucoma , cataract , retinal disorders, severe corneal disease)

Ocular surgery within the past 12 months

Chronic systemic diseases (e.g., uncontrolled diabetes, autoimmune disease, severe liver/kidney impairment, cancer)

Trial design

Treatments tested in this trial

  • Placebo
  • BL531_low dose
  • BL531_high dose
  • LR1349_low dose
  • LR1349_high dose

Treatment groups

150 Participants
are divided into 5 treatment groups

Sponsors and collaborators